Serum creatinine levels in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis

References

• Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
   PubMed Web of Science ®Google Scholar
• Morgan S, Orrell RW. Pathogenesis of amyotrophic lateral sclerosis. Br Med Bull. 2016;119:87–98.
   PubMed Web of Science ®Google Scholar
• Wei Q, Chen X, Zheng Z, Guo X, Huang R, Cao B, et al. The predictors of survival in Chinese amyotrophic lateral sclerosis patients. Amyotroph Lat Scl Fr. 2015;16:237–44.
   PubMed Web of Science ®Google Scholar
• Chiò A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82:740–6.
   PubMed Web of Science ®Google Scholar
• Bacci ED, Staniewska D, Coyne KS, Boyer S, White LA, Zach N, et al. Item response theory analysis of the amyotrophic lateral sclerosis functional rating scale-revised in the pooled resource open-access ALS clinical trials database. Amyotroph Lat Scl Fr. 2016;17:157–67.
   PubMed Web of Science ®Google Scholar
• Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PloS One. 2016;11:e0164625.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Zhang M, Quiroz Zárate A, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012;259:1923–8.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51:1501–8.
   PubMed Web of Science ®Google Scholar
• Tetsuka S, Morita M, Ikeguchi K, Nakano I. Utility of cystatin C for renal function in amyotrophic lateral sclerosis. Acta Neurol Scand. 2013;128:386–90.
   PubMed Web of Science ®Google Scholar
• Ren Y, Zhu W, Cui F, et al. Evaluation of serum creatinine level in amyotrophic lateral sclerosis patients. Chin J Internal Med. 2014;53:283–5.
   PubMedGoogle Scholar
• Duan Y, Fan D. Association of serum uric acid level with amyotrophic lateral sclerosis. Nat Med J China 2016;96:207–9.
   Google Scholar
• Chen X, Wei Q-Q, Chen Y, Cao B, Ou R, Hou Y, et al. Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. Amyotroph Lat Scl Fr. 2019;20:53–60.
   PubMed Web of Science ®Google Scholar
• Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lat Scl Fr. 2014;15:362–70.
   PubMed Web of Science ®Google Scholar
• Chen X, Guo X, Huang R, Zheng Z, Chen Y, Shang H-f, et al. An exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosis. Neurol Sci. 2014;35:1591–7.
   PubMed Web of Science ®Google Scholar
• Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012;13:110–8.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D'Errico E, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol. 2011;258:238–43.
   PubMed Web of Science ®Google Scholar
• Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V, et al. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:37–44.
   PubMed Web of Science ®Google Scholar
• Chiò A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71:1134–42.
   PubMed Web of Science ®Google Scholar
• Lunetta C, Lizio A, Melazzini MG, Maestri E, Sansone VA. Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): a simple scoring system for early prediction of patient survival. Amyotroph Lat Scl Fr. 2015;17:93–100.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Rosi E, Fini N, Fasano A, Raggi S, Fantuzzi AL, et al. Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis. Neurol Sci. 2017;38:2177–82.
   PubMed Web of Science ®Google Scholar
• Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol. 2008;3:348–54.
   PubMed Web of Science ®Google Scholar
• Patel SS, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013;4:19–29.
   PubMed Web of Science ®Google Scholar
• Tetsuka S, Morita M, Ikeguchi K, Nakano I. Creatinine/cystatin C ratio as a surrogate marker of residual muscle mass in amyotrophic lateral sclerosis. Neurol Clin Neurosci. 2013;1:32–7.
   Google Scholar
• Paganoni S, Nicholson K, Chan J, Shui A, Schoenfeld D, Sherman A, et al. Urate levels predict survival in amyotrophic lateral sclerosis: analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. Muscle Nerve. 2018;57:430–4.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
   PubMed Web of Science ®Google Scholar
• Mittlböck M, Heinzl H. A simulation study comparing properties of heterogeneity measures in meta-analyses. Stat Med. 2006;25:4321–33.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
   PubMed Web of Science ®Google Scholar
• Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lat Scl Fr. 2014;15:406–13.
   PubMed Web of Science ®Google Scholar
• Küffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51–7.
   PubMed Web of Science ®Google Scholar
• Wu J, Wuolikainen A, Trupp M, Jonsson P, Marklund SL, Andersen PM, et al. NMR analysis of the CSF and plasma metabolome of rigorously matched amyotrophic lateral sclerosis, Parkinson’s disease and control subjects. Metabolomics 2016;12:101–13.
   Web of Science ®Google Scholar
• Wuolikainen A, Jonsson P, Ahnlund M, Antti H, Marklund SL, Moritz T, et al. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. Mol Biosyst. 2016;12:1287–98.
   PubMedGoogle Scholar
• Patin F, Corcia P, Madji Hounoum B, Veyrat-Durebex C, Respaud E, Piver E, et al. Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. Eur J Neurol. 2015;22:1385–90.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kawabe K, Iwasaki Y. Do serum uric acid levels reflect oxidative stress in the progression of ALS? J Neurol Sci. 2009;287:294–5.
   PubMed Web of Science ®Google Scholar
• Wei Q-Q, Chen Y, Chen X, Cao B, Ou R, Zhang L, et al. Prognostic nomogram associated with longer survival in amyotrophic lateral sclerosis patients. Aging Dis. 2018;9:965–75.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, van den Berg LH, et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2018;89:156–61.
   PubMed Web of Science ®Google Scholar
• Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database design, initial analyses, and predictive features. Neurology 2014;83:1719–25.
   PubMed Web of Science ®Google Scholar
• Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC, et al. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258:613–7.
   PubMed Web of Science ®Google Scholar
• Tai H Cui L, et al. Research progress of serum creatinine levels in patients with amyotrophic lateral sclerosis. Chin J Internal Med. 2017;56:136–9.
   PubMedGoogle Scholar
• Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265–7.
   PubMed Web of Science ®Google Scholar
• Reich-Slotky R, Andrews J, Cheng B, Buchsbaum R, Levy D, Kaufmann P, et al. Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lat Scl Fr. 2013;14:212–6.
   PubMed Web of Science ®Google Scholar
• Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, et al. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. J Neurol. 2019;266:2952–61.
   PubMed Web of Science ®Google Scholar
• Vucic S. Plasma creatinine: a potential prognostic biomarker in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2018;89:119
   PubMed Web of Science ®Google Scholar
• Loeffler J-P, Picchiarelli G, Dupuis L, Gonzalez De Aguilar J-L. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol. 2016;26:227–36.
   PubMed Web of Science ®Google Scholar
• Beal MF. Neuroprotective effects of creatine. Amino Acids. 2011;40:1305–13.
   PubMed Web of Science ®Google Scholar